| It is important that HCPs are educated about the differences between standard formulary insulins and second-generation insulins, and the importance of clear communication during patient transitions (Diabetes Therapy)
This article summarises the evidence regarding the use of SGLT2i medicines in slowing the progression of DKD and examines the possible mechanisms underpinning the renoprotective effects of these agents (Diabetes Therapy)
In this review, we have summarized the results reported globally and found that the genetic variants of GCK and OCT3 genes is a risk factor for T2DM while G6PC2 and GCKR genes are controversial in different ethnic groups (Diabetes, Metabolic Syndrome)
These data confirm a beneficial effect of intensive glycemic therapy and demonstrate, for the first time, a similar benefit of intensive BP control on CAN in T2D. A negative CVD history identifies T2D patients who especially benefit from intensive glycemic control for CAN prevention (Diabetes Care)
This report is part of an initiative led by Lesley Mills (Nurse Consultant); the group included Diabetes Specialist Nurses and Practitioners, Consultants (ABCD, Diabetes UK)
In patients with T2DM and CVD, the incidence of cardioprotective GLD initiation increased between 2012‐18, however within two years after dual diagnosis, it remained low (Diabetes, Obesity and Metabolism)
Effect of liraglutide vs. placebo treatment on circulating proglucagon‐derived peptides that mediate improvements in body weight, insulin secretion and action (Diabetes, Obesity and Metabolism)
| 